1. Scrip
  2. >>New Products

AbbVie Broadens Qulipta Migraine Indication As Anti-CGRP Competition Grows

Approval Comes Month After New Pfizer Product

 
• By Mandy Jackson

AbbVie’s migraine franchise expanded with US FDA approval of Qulipta for chronic migraine prevention, but its CGRP inhibitors are facing off against a pair of rivals acquired by Pfizer last year.

Tired african-american business woman with headache at office, feeling sick at work, copy space
Qulipta cut headache days significantly for chronic migraine sufferers

AbbVie Inc. has a multi-modality migraine drug franchise, now expanded with a broader US label for its oral CGRP inhibitor Qulipta (atogepant) in migraine prevention, but the company is facing tough competition in the anti-CGRP space, which recently added yet another approved product with a first-in-class route of administration.

Qulipta won US Food and Drug Administration approval for the prevention of episodic migraine (14 headaches or fewer per month) in September 2021 and gained FDA approval for the prevention of chronic migraine (15 headaches or more per month) on 17 April

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.